European Companies Search Engine
UK funding (£849,632): Development of prognostic epigenetic biomarkers for ALS. Ukri1 Apr 2015 UK Research and Innovation, United Kingdom
Overview
Text
Development of prognostic epigenetic biomarkers for ALS.
| Abstract | Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with no blood-based diagnostic or prognostic test available. The current management of ALS is supportive, palliative, and multidisciplinary with the only approved therapy, riluzole, having a modest efficacy. Recent late stage clinical failures are thought in part to be due to the existence of disease subtypes in ALS. Biomarkers, especially those connected to different disease processes, would be valuable for stratifying individuals in trial recruitment and to measure treatment effect within each group. OBD and partners are seeking to validate a panel of epigenetic markers, obtained through earlier research, to enable the development of a diagnostic and prognostic test for ALS. This test will enable the stratification of ALS patients with fast vs. slow progressing disease for use as a companion test for novel targeted therapeutic approaches, as a trial selection tool and indicator of treatment efficacy. Additionally the test will have value as a standalone prognostic to inform the wider clinical management of patients. |
| Category | Collaborative R&D |
| Reference | 102168 |
| Status | Closed |
| Funded period start | 01/04/2015 |
| Funded period end | 31/12/2017 |
| Funded value | £849,632.00 |
| Source | https://gtr.ukri.org/projects?ref=102168 |
Participating Organisations
| Oxford Biodynamics Plc |
£613,041.00 |
| University of Oxford |
£229,240.00 |
| Chronos Therapeutics Limited |
£7,351.00 |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Oxford Biodynamics plc, Oxford.
The visualizations for "Oxford Biodynamics plc - UK funding (£849,632): Development of prognostic epigenetic biomarkers for ALS."
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
